| abstract |
The disclosure is directed in part to extended release compositions that include hydroxy progesterone caproate. For example, provided herein is a therapeutic microparticle composition comprising a plurality of microparticles, wherein the microparticles each comprise poly (lactide-co-glycolide) and hydroxyprogesterone caproate. |